Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Should We Use Ultrasound Routinely to Guide Transfemoral Access?

Currently, transfemoral access (TFA) is used in large-caliber procedures and when transradial access fails. The introduction of ultrasound (US) to guide access has emerged as a technique that allows for precise channeling, avoiding accesses above or below the inguinal ligament. However, evidence regarding the use of this tool has shown diverse results. Two surveys conducted among interventional cardiologists revealed that only 13-27% of them use US, despite 88% indicating that this technology was available in the cath lab.

¿Deberíamos adoptar el uso rutinario del ultrasonido para guiar el acceso femoral?

The aim of this meta-analysis was to compare the use of US to guide TFA versus its absence.

The primary endpoint (PEP) was a composite of major vascular complications (including pseudoaneurysms, arteriovenous fistulas, retroperitoneal bleeding, hematomas with diameter >5 cm, limb ischemia requiring intervention or surgery) or major bleeding according to BARC classification 3 or 5. The secondary endpoint (SEP) was a composite of major vascular complications, major or minor bleeding, and major vascular complications, exclusively.

The analysis included a total of 2441 patients; 1208 of them were randomized to the US-guided access group and 1233 to the non-US-guided access group. Mean patient age was 65.5 years, and most subjects were men. Overall, 12% of patients had peripheral vascular disease, and 34% underwent coronary transluminal angioplasty. A 6-Fr catheter was used in approximately 80% of cases, and percutaneous device closure was applied in half of the cases.

Read also: Short-Term Outcomes of TAVR in Asymptomatic or Minimally Symptomatic Patients.

In terms of results, the incidence of major vascular complications or major bleeding was lower in the US-guided group (2.8% vs 4.5%; odds ratio [OR]: 0.61, 95% confidence interval [CI]: 0.39-0.94; p=0.026). In the subgroup of patients who received closure devices, those randomized to the US-guided arm experienced a reduction in the rates for major bleeding or major vascular complications (2.1% vs 5.6%; OR: 0.36; 95% CI: 0.19-0.69), while there was no benefit for patients in the subgroup without closure device (4.1% vs 3.3%; OR: 1.21; 95% CI: 0.65-2.26).

Conclusion

This meta-analysis showed that the use of US to guide TFA is associated with a lower risk of major bleeding or major vascular complications in coronary procedures. In addition, this strategy may be useful in preventing vascular complications in patients receiving closure devices. Routine incorporation of ultrasound to guide transfemoral access should be considered.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Ultrasound guidance for transfemoral access in coronary procedures: an individual participant-level data meta-analysis from the femoral ultrasound trialist collaboration.

Reference: Marc-André d’Entremont, MD, MPH et al EuroIntervention 2023;19-online publish-ahead-of-print October 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...